BJERKHOLT ERIC sold $611K of MIRM
BJERKHOLT ERIC (CHIEF FINANCIAL OFFICER) sold 5,000 shares of Mirum Pharmaceuticals, Inc. (MIRM) at an average of $122.25 ($121.67–$124.94, $0.61M total) across 4 trades on 2026-07-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only new fact is the CFO’s planned open-market sale details and post-transaction holdings; it does not include new guidance, trial results, or corporate actions.
Market read
Traders may monitor for patterns in insider activity, but this specific filing is unlikely to drive a fundamental repricing.
What to watch
10b5-1 plans often reflect scheduled liquidity needs (taxes, diversification) and may not correlate with near-term business outlook.
Background
The article is an SEC Form 4 insider transaction disclosure for Mirum Pharmaceuticals, Inc.
Ticker impact
Mirum Pharmaceuticals CFO Eric Bjerkholt sold about $611K of MIRM shares via an open-market sale under a 10b5-1 plan on July 6.
Limited near-term impact; any reaction is likely muted and short-lived unless follow-on filings show unusual selling patterns.
The filing is a Form 4 open-market sale by the CFO with an explicit pre-arranged 10b5-1 plan, providing no new company fundamentals or guidance.
Market effects
No clear sector read-through from a single planned insider sale.
None indicated.
None indicated.
Counterpoint
Insider selling can still be interpreted as confidence erosion, especially if it accelerates or is paired with other negative signals, even when executed under 10b5-1.
Key entities
- issuerMirum Pharmaceuticals, Inc.
Subject of the Form 4 insider sale disclosure.
- insiderEric BJERKHOLT
Chief Financial Officer who sold shares under a pre-arranged 10b5-1 plan.
